HealthdirectFree Australian health advice you can count on.

( ARTG ) Early Breast Cancer VERZENIO in combination with endocrine therapy is indicated for the adjuvant treatment of patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node-positive early breast cancer at high risk of recurrence.,In pre- or per‍‍‍‍‍‍​​​‍​​​​​​i-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.,Advanced or Metastatic Breast Cancer VERZENIO is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or following prior endocrine therapy.,In pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.